Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3029% below fair value
$61.35−1.58 (-2.51%)
Close on Nov 17, 2026Market cap $125.40BP/E 13.6Yield 4.06%
Bristol Myers Squibb EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Bristol Myers Squibb's EV/EBITDA was 9.6× on Nov 11, 2026, against 8.9× a year earlier. Over the last 5 years it ranged from 6.1× to 51.3×, with a median of 9.6×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 9.6× | −0.0 |
| 2025 | Dec 31, 2025 | 9.6× | −21.3 |
| 2024 | Dec 31, 2024 | 30.9× | +23.8 |
| 2023 | Dec 29, 2023 | 7.0× | −2.6 |
| 2022 | Dec 30, 2022 | 9.6× | −11.4 |
| 2021 | Dec 31, 2021 | 21.1× | +9.5 |
| 2020 | Dec 31, 2020 | 11.6× | −1.0 |
| 2019 | Dec 31, 2019 | 12.6× | −1.6 |
| 2018 | Dec 31, 2018 | 14.3× | −1.8 |
| 2017 | Dec 29, 2017 | 16.1× | −4.1 |
| 2016 | Dec 30, 2016 | 20.2× | −18.5 |
| 2015 | Dec 31, 2015 | 38.8× | +14.4 |
| 2014 | Dec 31, 2014 | 24.4× | −2.0 |
| 2013 | Dec 31, 2013 | 26.4× | +12.1 |
| 2012 | Dec 31, 2012 | 14.3× | – |
See a number that looks wrong?